Amarin Q4 2018 Conference Call--Strong Sales & High Confidence
Q4 2018 Revenues Stronger Than Pre-Announcement on January 4th: Amarin released its Q4 2018 results today and held a conference call. Results of...
856 Views
Amarin--2019's Biggest Buyout Target for Big Pharma
Amarin (AMRN US), a US-listed biotech firm, presented the full results of its "Reduce-It" (RI) clinical trial at a conference for the American...
4.9k Views
Nippon Suisan (1332)--Stalled EPA Sales to Amarin
Nippon Suisan ("Nissui") has a new fish-oil EPA plant with 420 tons/year in capacity and is currently operating at 50% utilization. The company...
2.6k Views
Nippon Suisan--Amarin Reports 25% Risk Reduction in Clinical Trial, Better than Lipitor Results
We wrote a report on Nippon Suisan ("Nissui"), a 110-year-old fish trader and food products company in Japan, on September 3rd (Nippon Suisan...
1.7k Views
Nippon Suisan (1332)--Update on Amarin's Reduce-It Trial Data Scheduled for Release by Month-End
We recently published an Insight (Nippon Suisan (1332)--The Biggest Event in Japan's Food & Beverage Sector Comes Within 4 Weeks) on Japanese...
1.3k Views